1Wagner GS,Freye CJ,Palmeri ST,et al.Evaluation of a QRS scoring system for estimating myocardial infarct size.I.Specificity and observer agreement[J].Circulation,1982,65(2):342-347.
2Ideker RE,Wagner GS,Ruth WK,et al.Evaluation of a QRS scoring system for estimating myocardial infarct size.II.Correlation with quantitative anatomic findings for anterior infarcts[J].Am J Cardiol,1982,49(7):1604-1614.
3Hindman NB,Schocken DD,Widmann M,et al.Evaluation of a QRS scoring system for estimating myocardial infarct size.V.Specificity and method of application of the complete system[J].Am J Cardiol,1985,55(13 Pt 1):1485-1490.
4Aldrich HR,Wagner NB,Boswick J,et al.Use of initial ST-segment deviation for prediction of final electrocardiographic size of acute myocardial infarcts[J].Am J Cardiol,1988,61(10):749-753.
5Clemmensen P,Grande P,Aldrich HR,et al.Evaluation of formulas for estimating the final size of acute myocardial infarcts from quantitative ST-segment elevation on the initial standard 12-lead ECG[J].J Electrocardiol,1991,24(1):77-83.
6Clemmensen P,Grande P,Pedersen F,et al.ECG and enzymatic indicators of therapeutic success after intravenous streptokinase for acute myocardial infarction[J].Am Heart J,1990,120(3):503-509.
7Ripa RS,Holmyang L,Maynard C,et al.Consideration of the total ST-segment deviation on the initial electrocardiogram for predicting final acute posterior myocardial infarct size in patients with maximum ST-segment deviation as depression in leads V1 through V3.A FRISC II substudy[J].J Electrocardiol,2005,38(3):180-186.
8Beller GA,Zaret BL.Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease[J].Circulation,2000,101(12):1465-1478.
9Beller GA,Brown KA.The VANQWISH Trial:support for the noninvasive strategy for risk stratification after acute myocardial infarction[J].J Nucl Cardiol,1998,5(6):634-642.
10Bonow RO.Identification of viable myocardium[J].Circulation,1996,94(11):2674-2680.
5Brown DA, Breit SN, Buring J, et al. Concentration in plasma of Mac- rophagein hibitorycy tokine - 1 and risk of cardio vascularenents in women : anested case control study [ J ]. Lancet, 2002,359 ( 9324 ) : 2159 - 2163.
6Skin AR, Brown DA, Kuffner T, et al. Role of macrophage in - hibito- ry cytokine - 1 in tumorigenesis and diagnosis of cancer [ J ]. Cancer Res ,2006,66 (10) :4983 - 4986.
7Kempf T, Bjorklund E, Olofsson S, et al. Growth - differentiation Fac- tor - 15 improves risk stratification in ST - segment elevation myocardial infarction[ J]. Eur Heart J ,2007,28 ( 23 ) :2858 - 2865.
8Eggers KM, Kempf T, Allhoff T, et al. Growth - differentiation factor -15 for early risk stratification in patients with acute chest pain[ J]. Eur Heart J,2008,29(19) :2327,2335.
9Schaub N, Reichlin T, Twerenbold R, et al. Growth differentiation fac- tor- 15 in the early diagnosis and risk stratification of patients with a- cute chest pain[ J]. Clin Chem,2012,58(2) :441 -449.
10Bauskin AR, Zhang HP, Faidie WD, et al. The propeptide of macro- phage inhibitory cytokine( MIC - 1 ) ,a TGF - beta superfamily member, acts as a quality control determinant for correctly folded MIC - 1 [ J ]. EMBO J,2000,19 (10) :2212 - 2220.
